NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
MIDTERM EXAM – NURS6521 / NURS 6521 (LATEST 2026
/ 2027)
Advanced Pharmacology – Walden University
Graduate Nursing & Advanced Practice Education
150 Questions • 9 Sections • Cognitive Mix: 20% Recall / 50% Application / 30% Analysis
Aligned with Walden NURS 6521 Syllabus, AACN Essentials of Master’s Education, and Advanced Pharmacology
Competencies
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient is prescribed oral propranolol for atrial fibrillation. The nurse practitioner
understands that the first-pass effect will significantly reduce the drug's bioavailability. Which statement best
explains the clinical implication of the first-pass effect for this medication?
A. Bioavailability is increased because the drug bypasses hepatic metabolism.
B. A larger oral dose is required compared with the IV dose to achieve the same systemic effect.
*[CORRECT]*
C. The drug must always be given intravenously to be effective.
D. First-pass effect only applies to water-soluble drugs administered sublingually.
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a portion of an orally administered drug before it reaches
systemic circulation, reducing bioavailability. Consequently, oral doses must be larger than IV doses to achieve equivalent
therapeutic effect. Propranolol undergoes extensive first-pass metabolism (~70%), so oral bioavailability is much lower than IV.
The other options misstate the mechanism or incorrectly claim IV-only administration.
Q2: A patient receives a drug with a half-life of 12 hours. The medication is ordered once daily.
Approximately how long will it take to reach steady-state plasma concentrations assuming no loading dose is
given?
A. 24 hours
B. 48 hours
C. 60 hours (about 5 half-lives) *[CORRECT]*
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4-5 half-lives regardless of dosing interval. With a 12-hour half-life, 5
half-lives equal 60 hours (~2.5 days). Giving a loading dose can achieve therapeutic levels sooner, but steady state still depends
on the elimination half-life. The other timeframes either underestimate (1-2 half-lives) or overestimate (10 half-lives) the
mathematical rule.
Page 1 Confidential – For Study Use Only
,NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q3: A 55-year-old with new-onset seizures is started on phenytoin. The provider elects to use a loading dose.
Which pharmacokinetic principle justifies administration of a loading dose for phenytoin?
A. It shortens the drug's half-life.
B. It rapidly achieves therapeutic plasma concentrations before steady state would otherwise be reached.
*[CORRECT]*
C. It decreases total body clearance of the drug.
D. It eliminates the need for maintenance dosing.
Correct Answer: B
Rationale: A loading dose rapidly fills the volume of distribution to achieve therapeutic plasma concentration quickly, which is
critical for drugs with long half-lives or urgent indications such as seizures, arrhythmias, and antibiotics. Phenytoin has a long
and dose-dependent half-life; without a loading dose, reaching steady state would take many days. Loading dose does not alter
half-life, clearance, or replace maintenance dosing.
Q4: A patient on warfarin (highly protein-bound) is newly started on sulfamethoxazole-trimethoprim. The
international normalized ratio (INR) rises significantly within three days. Which mechanism best explains this
interaction?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin metabolism.
B. Sulfamethoxazole displaces warfarin from albumin, transiently raising free warfarin and INR.
*[CORRECT]*
C. Sulfamethoxazole decreases warfarin absorption from the gut.
D. Sulfamethoxazole increases renal clearance of warfarin metabolites.
Correct Answer: B
Rationale: Warfarin is highly protein-bound to albumin. Sulfonamides also bind albumin and displace warfarin, transiently
increasing the free (active) fraction and elevating INR. Many sulfonamides additionally inhibit CYP2C9, further reducing
warfarin clearance. The displacement mechanism is the classic pharmacokinetic explanation; induction (option A) would lower
INR, and reduced absorption or increased clearance would also lower INR.
Q5: A patient has been taking carbamazepine for six months. Recently prescribed rifampin is added for
tuberculosis prophylaxis. The nurse practitioner anticipates which change in carbamazepine plasma levels?
A. Increased carbamazepine levels due to CYP450 inhibition.
B. Decreased carbamazepine levels due to CYP3A4 induction by rifampin. *[CORRECT]*
C. No change because the two drugs do not share metabolic pathways.
D. Increased carbamazepine levels due to P-glycoprotein inhibition.
Correct Answer: B
Rationale: Rifampin is a potent inducer of CYP3A4 (and other CYP isoenzymes), increasing hepatic metabolism of
carbamazepine and reducing its plasma concentration. Induction develops over 1-2 weeks and typically necessitates dose
increase of the affected drug. Inhibition (option A) would raise levels, and the no-change answer ignores the well-known
interaction.
Page 2 Confidential – For Study Use Only
,NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q6: A nursing student asks why digoxin, lithium, and warfarin require particularly close therapeutic drug
monitoring. The best reply is that these drugs:
A. Have a long half-life only.
B. Have a narrow therapeutic index where toxic and therapeutic doses are close. *[CORRECT]*
C. Are excreted only by the kidneys.
D. Are highly protein-bound in plasma.
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index (TI) have toxic concentrations very close to therapeutic concentrations, so
small dosing errors or physiologic changes can produce toxicity or therapeutic failure. Digoxin, lithium, and warfarin are classic
narrow-TI drugs requiring serum monitoring. Half-life, renal excretion, and protein binding contribute but are not the defining
feature.
Q7: A patient with schizophrenia is started on aripiprazole, a partial agonist at D2 receptors. Which
pharmacodynamic property best distinguishes a partial agonist from a full agonist?
A. A partial agonist always blocks receptor activity.
B. A partial agonist produces a submaximal response even at full receptor occupancy and can act as an
antagonist in the presence of a full agonist. *[CORRECT]*
C. A partial agonist has lower affinity but higher efficacy than a full agonist.
D. A partial agonist has no clinical effect on receptor function.
Correct Answer: B
Rationale: A partial agonist has affinity for the receptor but produces less than maximal (submaximal) efficacy, even when all
receptors are occupied. In the presence of a full agonist, a partial agonist behaves functionally as an antagonist by competing for
receptors while producing a smaller response. Aripiprazole stabilizes dopaminergic tone via this mechanism. The other options
mischaracterize partial agonism.
Q8: Two beta-1 selective antagonists are being compared: Drug X achieves 50% of maximal effect at 2 mg;
Drug Y achieves 50% of maximal effect at 10 mg. Both reach the same maximal effect at high doses. Which
statement is correct?
A. Drug Y is more potent than Drug X.
B. Drug X is more potent than Drug Y; both have equal efficacy. *[CORRECT]*
C. Drug X has higher efficacy than Drug Y.
D. Drug Y has higher efficacy than Drug X.
Correct Answer: B
Rationale: Potency refers to the dose required to produce a defined effect (typically EC50); the lower the dose needed, the
greater the potency. Drug X requires 2 mg versus Drug Y's 10 mg, so X is more potent. Efficacy refers to the maximal effect
achievable; since both reach the same maximum, efficacies are equal. Options C and D confuse potency with efficacy.
Page 3 Confidential – For Study Use Only
, NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q9: A 70 kg patient receives a loading dose of a medication. The drug's volume of distribution (Vd) is 0.5 L/kg
and the target plasma concentration is 5 mg/L. Using the formula Loading Dose = (Vd x Cp) / F, with oral
bioavailability F = 0.5, what loading dose is most appropriate?
A. 175 mg
B. 250 mg
C. 350 mg *[CORRECT]*
D. 500 mg
Correct Answer: C
Rationale: Vd total = 0.5 L/kg x 70 kg = 35 L. Loading Dose = (Vd x Cp) / F = (35 L x 5 mg/L) / 0.5 = .5 = 350 mg. The
other values reflect arithmetic errors such as forgetting the bioavailability correction or miscalculating Vd.
Q10: A 78-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73 m2) is prescribed a renally
cleared medication. Which pharmacokinetic change is most clinically important when dosing this patient?
A. Increased hepatic first-pass metabolism requiring higher doses.
B. Prolonged elimination half-life and reduced clearance requiring dose reduction. *[CORRECT]*
C. Enhanced protein binding increasing free drug levels.
D. Faster absorption from the gastrointestinal tract.
Correct Answer: B
Rationale: Renally cleared drugs have reduced clearance and prolonged half-life in CKD, leading to drug accumulation and
toxicity if dosing is not adjusted. Dose reduction or interval extension is required. Hepatic first-pass, protein binding, and GI
absorption are not directly affected by reduced GFR. The Beers Criteria and most drug references provide renal dose
adjustments.
Q11: A patient is prescribed a medication that undergoes extensive first-pass metabolism. Which route of
administration would bypass the first-pass effect most effectively?
A. Oral tablet
B. Sublingual *[CORRECT]*
C. Rectal suppository (lower rectum)
D. Enteric-coated tablet
Correct Answer: B
Rationale: Sublingual administration allows drug absorption through the oral mucosa directly into systemic circulation,
bypassing the portal circulation and hepatic first-pass metabolism. Nitroglycerin is the classic example. Rectal administration
partially bypasses first-pass (about 50% escapes the liver via middle and inferior rectal veins). Oral and enteric-coated forms
still undergo first-pass metabolism.
Q12: A patient taking digoxin is started on amiodarone. Two weeks later, the patient exhibits nausea, visual
disturbances, and confusion. The interaction is best explained by inhibition of which transporter/enzyme?
A. CYP3A4 and P-glycoprotein *[CORRECT]*
B. CYP2D6 only
C. Renal tubular secretion only
D. Hepatic glucuronidation only
Correct Answer: A
Rationale: Amiodarone inhibits both CYP3A4 and P-glycoprotein (P-gp), the major efflux transporter for digoxin. Inhibition of
P-gp reduces digoxin clearance and increases serum levels, producing classic digoxin toxicity (GI, visual, and CNS findings).
The other options omit P-gp or focus on metabolic pathways not central to digoxin disposition.
Page 4 Confidential – For Study Use Only
MIDTERM EXAM – NURS6521 / NURS 6521 (LATEST 2026
/ 2027)
Advanced Pharmacology – Walden University
Graduate Nursing & Advanced Practice Education
150 Questions • 9 Sections • Cognitive Mix: 20% Recall / 50% Application / 30% Analysis
Aligned with Walden NURS 6521 Syllabus, AACN Essentials of Master’s Education, and Advanced Pharmacology
Competencies
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient is prescribed oral propranolol for atrial fibrillation. The nurse practitioner
understands that the first-pass effect will significantly reduce the drug's bioavailability. Which statement best
explains the clinical implication of the first-pass effect for this medication?
A. Bioavailability is increased because the drug bypasses hepatic metabolism.
B. A larger oral dose is required compared with the IV dose to achieve the same systemic effect.
*[CORRECT]*
C. The drug must always be given intravenously to be effective.
D. First-pass effect only applies to water-soluble drugs administered sublingually.
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a portion of an orally administered drug before it reaches
systemic circulation, reducing bioavailability. Consequently, oral doses must be larger than IV doses to achieve equivalent
therapeutic effect. Propranolol undergoes extensive first-pass metabolism (~70%), so oral bioavailability is much lower than IV.
The other options misstate the mechanism or incorrectly claim IV-only administration.
Q2: A patient receives a drug with a half-life of 12 hours. The medication is ordered once daily.
Approximately how long will it take to reach steady-state plasma concentrations assuming no loading dose is
given?
A. 24 hours
B. 48 hours
C. 60 hours (about 5 half-lives) *[CORRECT]*
D. 120 hours
Correct Answer: C
Rationale: Steady state is reached after approximately 4-5 half-lives regardless of dosing interval. With a 12-hour half-life, 5
half-lives equal 60 hours (~2.5 days). Giving a loading dose can achieve therapeutic levels sooner, but steady state still depends
on the elimination half-life. The other timeframes either underestimate (1-2 half-lives) or overestimate (10 half-lives) the
mathematical rule.
Page 1 Confidential – For Study Use Only
,NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q3: A 55-year-old with new-onset seizures is started on phenytoin. The provider elects to use a loading dose.
Which pharmacokinetic principle justifies administration of a loading dose for phenytoin?
A. It shortens the drug's half-life.
B. It rapidly achieves therapeutic plasma concentrations before steady state would otherwise be reached.
*[CORRECT]*
C. It decreases total body clearance of the drug.
D. It eliminates the need for maintenance dosing.
Correct Answer: B
Rationale: A loading dose rapidly fills the volume of distribution to achieve therapeutic plasma concentration quickly, which is
critical for drugs with long half-lives or urgent indications such as seizures, arrhythmias, and antibiotics. Phenytoin has a long
and dose-dependent half-life; without a loading dose, reaching steady state would take many days. Loading dose does not alter
half-life, clearance, or replace maintenance dosing.
Q4: A patient on warfarin (highly protein-bound) is newly started on sulfamethoxazole-trimethoprim. The
international normalized ratio (INR) rises significantly within three days. Which mechanism best explains this
interaction?
A. Sulfamethoxazole induces CYP2C9, accelerating warfarin metabolism.
B. Sulfamethoxazole displaces warfarin from albumin, transiently raising free warfarin and INR.
*[CORRECT]*
C. Sulfamethoxazole decreases warfarin absorption from the gut.
D. Sulfamethoxazole increases renal clearance of warfarin metabolites.
Correct Answer: B
Rationale: Warfarin is highly protein-bound to albumin. Sulfonamides also bind albumin and displace warfarin, transiently
increasing the free (active) fraction and elevating INR. Many sulfonamides additionally inhibit CYP2C9, further reducing
warfarin clearance. The displacement mechanism is the classic pharmacokinetic explanation; induction (option A) would lower
INR, and reduced absorption or increased clearance would also lower INR.
Q5: A patient has been taking carbamazepine for six months. Recently prescribed rifampin is added for
tuberculosis prophylaxis. The nurse practitioner anticipates which change in carbamazepine plasma levels?
A. Increased carbamazepine levels due to CYP450 inhibition.
B. Decreased carbamazepine levels due to CYP3A4 induction by rifampin. *[CORRECT]*
C. No change because the two drugs do not share metabolic pathways.
D. Increased carbamazepine levels due to P-glycoprotein inhibition.
Correct Answer: B
Rationale: Rifampin is a potent inducer of CYP3A4 (and other CYP isoenzymes), increasing hepatic metabolism of
carbamazepine and reducing its plasma concentration. Induction develops over 1-2 weeks and typically necessitates dose
increase of the affected drug. Inhibition (option A) would raise levels, and the no-change answer ignores the well-known
interaction.
Page 2 Confidential – For Study Use Only
,NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q6: A nursing student asks why digoxin, lithium, and warfarin require particularly close therapeutic drug
monitoring. The best reply is that these drugs:
A. Have a long half-life only.
B. Have a narrow therapeutic index where toxic and therapeutic doses are close. *[CORRECT]*
C. Are excreted only by the kidneys.
D. Are highly protein-bound in plasma.
Correct Answer: B
Rationale: Drugs with a narrow therapeutic index (TI) have toxic concentrations very close to therapeutic concentrations, so
small dosing errors or physiologic changes can produce toxicity or therapeutic failure. Digoxin, lithium, and warfarin are classic
narrow-TI drugs requiring serum monitoring. Half-life, renal excretion, and protein binding contribute but are not the defining
feature.
Q7: A patient with schizophrenia is started on aripiprazole, a partial agonist at D2 receptors. Which
pharmacodynamic property best distinguishes a partial agonist from a full agonist?
A. A partial agonist always blocks receptor activity.
B. A partial agonist produces a submaximal response even at full receptor occupancy and can act as an
antagonist in the presence of a full agonist. *[CORRECT]*
C. A partial agonist has lower affinity but higher efficacy than a full agonist.
D. A partial agonist has no clinical effect on receptor function.
Correct Answer: B
Rationale: A partial agonist has affinity for the receptor but produces less than maximal (submaximal) efficacy, even when all
receptors are occupied. In the presence of a full agonist, a partial agonist behaves functionally as an antagonist by competing for
receptors while producing a smaller response. Aripiprazole stabilizes dopaminergic tone via this mechanism. The other options
mischaracterize partial agonism.
Q8: Two beta-1 selective antagonists are being compared: Drug X achieves 50% of maximal effect at 2 mg;
Drug Y achieves 50% of maximal effect at 10 mg. Both reach the same maximal effect at high doses. Which
statement is correct?
A. Drug Y is more potent than Drug X.
B. Drug X is more potent than Drug Y; both have equal efficacy. *[CORRECT]*
C. Drug X has higher efficacy than Drug Y.
D. Drug Y has higher efficacy than Drug X.
Correct Answer: B
Rationale: Potency refers to the dose required to produce a defined effect (typically EC50); the lower the dose needed, the
greater the potency. Drug X requires 2 mg versus Drug Y's 10 mg, so X is more potent. Efficacy refers to the maximal effect
achievable; since both reach the same maximum, efficacies are equal. Options C and D confuse potency with efficacy.
Page 3 Confidential – For Study Use Only
, NURS 6521 Advanced Pharmacology | Midterm Exam (2026/2027) Walden University
Q9: A 70 kg patient receives a loading dose of a medication. The drug's volume of distribution (Vd) is 0.5 L/kg
and the target plasma concentration is 5 mg/L. Using the formula Loading Dose = (Vd x Cp) / F, with oral
bioavailability F = 0.5, what loading dose is most appropriate?
A. 175 mg
B. 250 mg
C. 350 mg *[CORRECT]*
D. 500 mg
Correct Answer: C
Rationale: Vd total = 0.5 L/kg x 70 kg = 35 L. Loading Dose = (Vd x Cp) / F = (35 L x 5 mg/L) / 0.5 = .5 = 350 mg. The
other values reflect arithmetic errors such as forgetting the bioavailability correction or miscalculating Vd.
Q10: A 78-year-old patient with chronic kidney disease (eGFR 28 mL/min/1.73 m2) is prescribed a renally
cleared medication. Which pharmacokinetic change is most clinically important when dosing this patient?
A. Increased hepatic first-pass metabolism requiring higher doses.
B. Prolonged elimination half-life and reduced clearance requiring dose reduction. *[CORRECT]*
C. Enhanced protein binding increasing free drug levels.
D. Faster absorption from the gastrointestinal tract.
Correct Answer: B
Rationale: Renally cleared drugs have reduced clearance and prolonged half-life in CKD, leading to drug accumulation and
toxicity if dosing is not adjusted. Dose reduction or interval extension is required. Hepatic first-pass, protein binding, and GI
absorption are not directly affected by reduced GFR. The Beers Criteria and most drug references provide renal dose
adjustments.
Q11: A patient is prescribed a medication that undergoes extensive first-pass metabolism. Which route of
administration would bypass the first-pass effect most effectively?
A. Oral tablet
B. Sublingual *[CORRECT]*
C. Rectal suppository (lower rectum)
D. Enteric-coated tablet
Correct Answer: B
Rationale: Sublingual administration allows drug absorption through the oral mucosa directly into systemic circulation,
bypassing the portal circulation and hepatic first-pass metabolism. Nitroglycerin is the classic example. Rectal administration
partially bypasses first-pass (about 50% escapes the liver via middle and inferior rectal veins). Oral and enteric-coated forms
still undergo first-pass metabolism.
Q12: A patient taking digoxin is started on amiodarone. Two weeks later, the patient exhibits nausea, visual
disturbances, and confusion. The interaction is best explained by inhibition of which transporter/enzyme?
A. CYP3A4 and P-glycoprotein *[CORRECT]*
B. CYP2D6 only
C. Renal tubular secretion only
D. Hepatic glucuronidation only
Correct Answer: A
Rationale: Amiodarone inhibits both CYP3A4 and P-glycoprotein (P-gp), the major efflux transporter for digoxin. Inhibition of
P-gp reduces digoxin clearance and increases serum levels, producing classic digoxin toxicity (GI, visual, and CNS findings).
The other options omit P-gp or focus on metabolic pathways not central to digoxin disposition.
Page 4 Confidential – For Study Use Only
